The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.

Also called NCT02281838

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 142 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02281838
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02281838. Randomized; no masking; primary purpose treatment. Start 2011-08-01 (actual); primary completion 2021-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II
Acronym
ICH-ADAPT II
Condition
Intracerebral Hemorrhage
Intervention (Drug)
labetalol/hydralazine/enalapril
Lead sponsor
University of Alberta (class: other)

Record details

Record id
cardio:ct-nct02281838
Content hash
b46f118378a3cc420b0cfc138706a00d241608b44e0b775e01b202248362dac8